Annals of Oncology· @Annals_Oncology · X·· 1 天前评分70
正文 · 机器翻译
📢 #ESMO26 同期论文 - Atirmociclib 和 fulvestrant 用于既往接受环素依赖性激酶 4/6 抑制剂治疗后出现进展的 HR+/HER2– 晚期/转移性乳腺癌患者：随机 FourLight-1 试验的主要分析。
🔗https://tinyurl.com/449n4nu2
@hoperugo
101 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
1842O按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgFOURLIGHT-1
https://esmocongress.esmo.org来源：Annals of Oncology · x.com